Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase
One of the problems encountered in the use of tetrahydrouridine (THU, 2) and saturated 2-oxo-1,3-diazepine nucleosides as orally administered cytidine deaminase (CDA) inhibitors is their acid instability. Under acid conditions these compounds are rapidly converted into inactive ribopyranoside forms....
Saved in:
Published in | Journal of medicinal chemistry Vol. 29; no. 8; pp. 1374 - 1380 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Washington, DC
American Chemical Society
01.08.1986
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | One of the problems encountered in the use of tetrahydrouridine (THU, 2) and saturated 2-oxo-1,3-diazepine nucleosides as orally administered cytidine deaminase (CDA) inhibitors is their acid instability. Under acid conditions these compounds are rapidly converted into inactive ribopyranoside forms. A solution this problem was sought by functionalizing the acid-stable but less potent CDA inhibitor 1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (1) with the hope of increasing its potency to the level achieved with THU. The selection of the hydroxymethyl substituent at C-4, which led to the synthesis of 4-(hydroxymethyl)-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (10), 3,4-dihydro-4-(hydroxymethyl)-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (7), and 3,4,5,6-tetrahydro-4-(dihydroxymethyl)-1-beta-D-ribofuranosyl-2(1H)-p yrimidinone (28) was based on the transition-state (TS) concept. The key intermediate precursor, 4-[(benzoyloxy)methyl]-1-(2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)-2(H) -pyrimidinone (24), was obtained via the classical Hilbert-Johnson reaction between 2-methoxy-4-[(benzoyloxy)methyl]pyrimidine (20) and 2,3,5-tri-O-benzoyl-1-D-ribofuranosyl bromide (21). Deprotection of 24 afforded compound 10, while its sodium borohydride reduction products afforded compounds 7 and 28 after removal of the blocking groups. Syntheses of 3,4-dihydro-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (9) and 3,6-dihydro-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (8), which lack the hydroxymethyl substituent, was accomplished in a similar fashion. The new compounds bearing the hydroxymethyl substituent were more acid stable than THU, and their CDA inhibitory potency, expressed in terms of Ki values, spanned from 10(-4) to 10(-7) M in a manner consistent with the TS theory. Compound 7, in particular, was superior to its parent 1 and equipotent to THU (Ki = 4 X 10(-7) M) when examined against mouse kidney CDA. The superior acid stability of this compound coupled to its potent inhibitory properties against CDA should provide a means of testing oral combinations of rapidly deaminated drugs, viz. ara-C, without the complications associated with the acid instability of THU. |
---|---|
AbstractList | One of the problems encountered in the use of tetrahydrouridine (THU, 2) and saturated 2-oxo-1,3-diazepine nucleosides as orally administered cytidine deaminase (CDA) inhibitors is their acid instability. Under acid conditions these compounds are rapidly converted into inactive ribopyranoside forms. A solution this problem was sought by functionalizing the acid-stable but less potent CDA inhibitor 1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (1) with the hope of increasing its potency to the level achieved with THU. The selection of the hydroxymethyl substituent at C-4, which led to the synthesis of 4-(hydroxymethyl)-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (10), 3,4-dihydro-4-(hydroxymethyl)-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (7), and 3,4,5,6-tetrahydro-4-(dihydroxymethyl)-1-beta-D-ribofuranosyl-2(1H)-p yrimidinone (28) was based on the transition-state (TS) concept. The key intermediate precursor, 4-[(benzoyloxy)methyl]-1-(2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)-2(H) -pyrimidinone (24), was obtained via the classical Hilbert-Johnson reaction between 2-methoxy-4-[(benzoyloxy)methyl]pyrimidine (20) and 2,3,5-tri-O-benzoyl-1-D-ribofuranosyl bromide (21). Deprotection of 24 afforded compound 10, while its sodium borohydride reduction products afforded compounds 7 and 28 after removal of the blocking groups. Syntheses of 3,4-dihydro-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (9) and 3,6-dihydro-1-beta-D-ribofuranosyl-2(1H)-pyrimidinone (8), which lack the hydroxymethyl substituent, was accomplished in a similar fashion. The new compounds bearing the hydroxymethyl substituent were more acid stable than THU, and their CDA inhibitory potency, expressed in terms of Ki values, spanned from 10(-4) to 10(-7) M in a manner consistent with the TS theory. Compound 7, in particular, was superior to its parent 1 and equipotent to THU (Ki = 4 X 10(-7) M) when examined against mouse kidney CDA. The superior acid stability of this compound coupled to its potent inhibitory properties against CDA should provide a means of testing oral combinations of rapidly deaminated drugs, viz. ara-C, without the complications associated with the acid instability of THU. |
Author | Marquez, Victor E Kim, Chong Ho Mao, David T Haines, David R McCormack, John J |
Author_xml | – sequence: 1 givenname: Chong Ho surname: Kim fullname: Kim, Chong Ho – sequence: 2 givenname: Victor E surname: Marquez fullname: Marquez, Victor E – sequence: 3 givenname: David T surname: Mao fullname: Mao, David T – sequence: 4 givenname: David R surname: Haines fullname: Haines, David R – sequence: 5 givenname: John J surname: McCormack fullname: McCormack, John J |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8778931$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/3735306$$D View this record in MEDLINE/PubMed |
BookMark | eNptkM2LFDEQxYOsrLOrJ89CH8Q9SDQf3Z3MURZ3FVZUZhRvIZ1U2Izd6dlUNzj__WacYfAgFNTh_V59vAtylsYEhLzk7B1ngr_fDIzxRlvGlk_IgjeC0Vqz-owsGBOCilbIZ-QCccMYk1zIc3IulWwkaxfk12qXpnvAiNUYqu0uxyH6mKigZUeVZtfDiNEDVraUi57iZLseqpjuYxenMf81ut20t0HlwQ4xWYTn5GmwPcKLY78kP24-rq8_0buvt5-vP9xRK7WcaKcUaNW1qpwG1us68JaHEFirQq2C5k2QXtSuNF5LXzPRWC5q74IXOiyDvCRvDnO3eXyYASczRHTQ9zbBOKNR7bItBl7AtwfQ5RExQzDb8qzNO8OZ2edo_smx0K-OY-duAH9ij8EV_fVRt-hsH7JNLuIJ00rppdwvpQcs4gR_TrLNv02rpGrM-tvKiJ_N9y_rm1uzKvzVgbcOzWaccyrZ_ffAR1mYl9U |
CODEN | JMCMAR |
CitedBy_id | crossref_primary_10_1002_med_21795 crossref_primary_10_1016_0040_4020_89_80011_0 crossref_primary_10_1111_j_1755_5922_2012_00320_x crossref_primary_10_1002_cjoc_200990133 crossref_primary_10_1586_era_09_164 crossref_primary_10_1016_j_pharmthera_2018_02_006 crossref_primary_10_1007_BF00686478 crossref_primary_10_2165_11596690_000000000_00000 crossref_primary_10_1016_S0040_4039_99_01163_6 crossref_primary_10_1016_S0040_4039_00_96218_X crossref_primary_10_2165_11592770_000000000_00000 crossref_primary_10_1002_term_3365 crossref_primary_10_1016_j_bcp_2009_05_017 crossref_primary_10_1039_D3OB00392B crossref_primary_10_1021_ja973522w crossref_primary_10_18632_oncotarget_1319 crossref_primary_10_1016_S0927_0256_98_00029_9 crossref_primary_10_1016_j_cellsig_2011_02_003 crossref_primary_10_1038_sj_bjc_6603482 crossref_primary_10_1042_BST0320910 crossref_primary_10_1021_jm100348u crossref_primary_10_3390_ijms241612652 crossref_primary_10_1007_s12975_015_0397_7 crossref_primary_10_1016_j_ccr_2004_06_023 crossref_primary_10_1006_jcph_1999_6219 crossref_primary_10_1016_S0021_9258_18_83491_3 crossref_primary_10_1093_jnci_95_5_399 crossref_primary_10_1007_s10549_009_0420_3 crossref_primary_10_1016_j_exphem_2006_10_005 crossref_primary_10_1093_nar_gkn797 crossref_primary_10_1080_07328319208017823 crossref_primary_10_1093_nar_gkt1285 crossref_primary_10_1196_annals_1281_014 crossref_primary_10_1039_D1OB00705J crossref_primary_10_1007_s11010_011_1019_7 crossref_primary_10_1007_s11103_011_9816_7 crossref_primary_10_1002_ejoc_201301542 crossref_primary_10_1186_1476_4598_6_3 crossref_primary_10_3390_biom7010003 crossref_primary_10_1371_journal_pone_0012388 crossref_primary_10_1097_CAD_0b013e32833a4352 crossref_primary_10_3109_03602532_2014_995379 crossref_primary_10_2478_s11658_012_0024_5 crossref_primary_10_1016_j_tet_2008_09_079 crossref_primary_10_1128_MCB_24_3_1270_1278_2004 crossref_primary_10_1002_chin_198704320 crossref_primary_10_1021_jo0617666 crossref_primary_10_1038_nrd1930 crossref_primary_10_1016_0006_2952_93_90444_2 crossref_primary_10_1016_0167_4838_93_90143_F crossref_primary_10_1021_jp901678g crossref_primary_10_3109_14756369509042814 crossref_primary_10_1021_jm100189a crossref_primary_10_1080_00304948_2022_2136474 |
ContentType | Journal Article |
Copyright | 1986 INIST-CNRS |
Copyright_xml | – notice: 1986 INIST-CNRS |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1021/jm00158a009 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1520-4804 |
EndPage | 1380 |
ExternalDocumentID | 10_1021_jm00158a009 3735306 8778931 ark_67375_TPS_2V5QMTFG_S c274689078 |
Genre | Journal Article |
GroupedDBID | - 1WB 3EH 53G 55 55A 5GY 5RE 5VS 9M8 AABXI ABFLS ABMVS ABOCM ABPTK ACGFS ACJ ACS AENEX AFFNX AGXLV AJYGW ALMA_UNASSIGNED_HOLDINGS ANTXH AQSVZ BAANH CS3 DU5 F5P GJ HR JG JG~ L7B LG6 MVM NHB OHT P2P RNS ROL TN5 W1F WH7 X X7M XFK YZZ ZE2 ZGI --- -~X .55 .GJ .HR .K2 6TJ ABHMW ABJNI ACGFO AEQTP AHGAQ BSCLL GGK IH2 VG9 XSW YQT 1KJ 3O- 4.4 6P2 7~N AAHBH AAYOK ABQRX ABTAH ABUCX ADHLV AEESW AFEFF CUPRZ EBS ED~ EJD GNL IH9 IHE IQODW UBC UI2 VF5 ZY4 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-a383t-b77e87b67003ead84f161fff067f47f815f3d24c5f3143d4025a124dcfd28f9f3 |
IEDL.DBID | ACS |
ISSN | 0022-2623 |
IngestDate | Fri Aug 16 01:20:04 EDT 2024 Fri Aug 23 02:53:07 EDT 2024 Sat Sep 28 08:33:50 EDT 2024 Thu Oct 17 05:08:17 EDT 2024 Wed Jan 17 04:53:38 EST 2024 Thu Aug 27 13:42:35 EDT 2020 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Enzyme inhibitor Ureas Infrared spectrum Ribonucleoside NMR spectrum Pyrimidine nucleoside Biological activity Cytidine deaminase |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-a383t-b77e87b67003ead84f161fff067f47f815f3d24c5f3143d4025a124dcfd28f9f3 |
Notes | istex:0F2DBCE3063DF0C5DF88C143ADE2BEB0FE19250B ark:/67375/TPS-2V5QMTFG-S ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 3735306 |
PQID | 76961241 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_76961241 crossref_primary_10_1021_jm00158a009 pubmed_primary_3735306 pascalfrancis_primary_8778931 istex_primary_ark_67375_TPS_2V5QMTFG_S acs_journals_10_1021_jm00158a009 |
ProviderPackageCode | JG~ 55A AABXI ACS ACJ AGXLV ABMVS 1WB BAANH AQSVZ W1F ANTXH |
PublicationCentury | 1900 |
PublicationDate | 1986-08-01 |
PublicationDateYYYYMMDD | 1986-08-01 |
PublicationDate_xml | – month: 08 year: 1986 text: 1986-08-01 day: 01 |
PublicationDecade | 1980 |
PublicationPlace | Washington, DC |
PublicationPlace_xml | – name: Washington, DC – name: United States |
PublicationTitle | Journal of medicinal chemistry |
PublicationTitleAlternate | J. Med. Chem |
PublicationYear | 1986 |
Publisher | American Chemical Society |
Publisher_xml | – name: American Chemical Society |
SSID | ssj0003123 |
Score | 1.5239972 |
Snippet | One of the problems encountered in the use of tetrahydrouridine (THU, 2) and saturated 2-oxo-1,3-diazepine nucleosides as orally administered cytidine... |
SourceID | proquest crossref pubmed pascalfrancis istex acs |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1374 |
SubjectTerms | Adenosine Deaminase Inhibitors Animals Carbohydrates. Nucleosides and nucleotides Chemistry Cytidine Deaminase - antagonists & inhibitors Exact sciences and technology Kidney - enzymology Magnetic Resonance Spectroscopy Mice Nucleoside Deaminases - antagonists & inhibitors Nucleosides, nucleotides and oligonucleotides Organic chemistry Preparations and properties Pyrimidine Nucleosides - chemical synthesis Pyrimidinones - chemical synthesis Spectrophotometry, Ultraviolet Structure-Activity Relationship Tetrahydrouridine - pharmacology |
Title | Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase |
URI | http://dx.doi.org/10.1021/jm00158a009 https://api.istex.fr/ark:/67375/TPS-2V5QMTFG-S/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/3735306 https://search.proquest.com/docview/76961241 |
Volume | 29 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3Nb9MwFH9C2wEuDAYTZQx8mHqax-zYtXOcKsqENFTUDvUW2YktwiCd5lQi_PU8J02rjS8pki9-kuP37N_vye8D4JgJmyJsSJog-6ZCGoVHylrq8V5ImcShLfZ8-XF0cSU-LORiG0Rz_wWfs7dfv0dc16ZN09vliIjRxzofzzYXbsJ40hcF5wjn6zS8e8IRfvJwB352407-iOGQJuCO-K6Vxd-5Zos5kz2Y9Jk7XajJ9emqtqf5z98LOf77d57A4zXrJOedmTyFB67ah4fjvtnbPgynXQnr5oTMtxlZ4YQMyXRb3Lp5BotZUyFnDGUgS09umtgVDOGPcrqsHKlideRl7AAaiMEvLwuK9NN-c6SsvpS2jL19omDe1FHMkcKZGIwT3HO4mrybjy_oujsDNejV1tQq5bSyMc0nQXPUwiN59N4j_HmhvEZFJwUXOQ7IyQr0U6VBqyhyX3DtU58cwE6FS3sBRHFjkbowZpAg6bPCpEpangstYjEfdjYAXHDI1qcrZO3DOUfHZbuXAzju9ZrddHU6_jxt2Op8M8fcXsfQNiWz-XSW8c_y0-V88j6bDeDojlFsBLRSSPHYAN70RpKhquIri6ncchUyNUqRNQqccdDZzkY0UYlED-3l___mEB6xVI-6QMNXsFPfrtwRkp_avm5N_xfcIvqb |
link.rule.ids | 315,786,790,2782,27107,27955,27956,57091,57141 |
linkProvider | American Chemical Society |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Bb9MwFH6atsO4MBhMdDDmw9RTPRYnrp0jqugKrFNRM9RbZCexCNvSaU4lwq_nOWlSbRoCKZIvfpFjP-f7LL_3PYATL9AhwganPrJvGnAlcEtpTQ3-F0KPY1OLPU8vh5Or4MuCL7Zg0ObC4CAsvsnWl_gbdQHvw89bB-9S1dl6O1wgzjkiNJp3_13fY36rDc4Q1dfZeI-MHQol9gEK7bgJ_eWiIpXFiTFNRYu_U84aesZ7MO0GXUecXJ-uSn2a_H6k5_i_X_UCnq85KPnYOM1L2MqKfdgdtaXf9qE_awStqwGJNvlZdkD6ZLaRuq5ewWJeFcggbW7J0pC7ytUIQzCkjC6LjBROK3np6oFaovBJ8pQiGdU3GcmLH7nOXaUfZ5hUpTPLSJopF5pjs9dwNf4UjSZ0XauBKjzjllQLkUmhXdKPj84pA4NU0hiDYGgCYSQuu5-yIMEGGVqKp1au0EfSxKRMmtD4B7Bd4NDeABFMaSQynqeQLsmzVIWCa5YEMnDSPt5ZD3DANl7vNRvX1-gMjzGbuezBSbu88V2j2vF0t3699F0fdX_tAt0Ej6PZPGbf-bdpND6P5z04euAbnYEUAgmf14Pj1ldiXCp356KKbLmysRiGyCED7HHQuFBn6guf43nt8N9fcwy7k2h6EV98vvz6Fp55oRw2IYjvYLu8X2VHSItK_b7eDX8AkW0DFQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3da9swED9KC9te2q1bWbZ11UPJU91FshTZjyVb1n20pCQdeTOSbTH3wwmVA_X--p38FVo2xsCgF53Rx53uJ3T3O4BDynWIbkN4PqJvjwsl0aS09gyeCyEV2FRkz2fnw9NL_nUu5hswaHNhcBAW_2SrR3xn1cvENAwD9MPVrXPxgaoy9raEpNyZ4slo2p29PmV-yw_O0LM3GXmPhJ0niu0DT7TlFvXeRUYqi4tj6qoWf4edlfsZ78BFN_Aq6uT6eFXo4_jXI07H_5nZc9husCg5qZXnBWyk-S48HbUl4HahP6mJrcsjMlvnadkj0ieTNeV1-RLm0zJHJGkzSxaGLEtXKwydose8RZ6S3HEmL1xdUEsUfnGWeAhK9U1KsvxnpjNX8ccJxmXhxFKSpMqF6Nj0FVyOP81Gp15Ts8FTeNctPC1lGkjtkn98VNKAG4SUxhh0ioZLE-D2-wnjMTaI1BK8vQqFupLEJmGBCY2_B5s5Du01EMmURkBDqULYFAwSFUqhWcwD7ih-6KAHOGAbNTZno-o5neF1Zr2WPThstzha1uwdf-7Wr7a_66Purl3AmxTRbDKN2A9xcTYbf46mPdh_oB-dQCAlAj_ag4NWXyLcKvf2ovJ0sbKRHIaIJTn22KvVqBP1pS_w3vbm37M5gCeTj-Po-5fzb2_hGQ2DYR2J-A42i7tVuo_oqNDvK4P4DfbdBY8 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synthesis+of+pyrimidin-2-one+nucleosides+as+acid-stable+inhibitors+of+cytidine+deaminase&rft.jtitle=Journal+of+medicinal+chemistry&rft.au=Kim%2C+Chong+Ho&rft.au=Marquez%2C+Victor+E&rft.au=Mao%2C+David+T&rft.au=Haines%2C+David+R&rft.date=1986-08-01&rft.pub=American+Chemical+Society&rft.issn=0022-2623&rft.eissn=1520-4804&rft.volume=29&rft.issue=8&rft.spage=1374&rft.epage=1380&rft_id=info:doi/10.1021%2Fjm00158a009&rft.externalDocID=c274689078 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-2623&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-2623&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-2623&client=summon |